Table 2.
Demographic characteristics of survival and non-survival groups during follow-up
| Variables | Non-survival group | Survival group | P values |
|---|---|---|---|
| No. of patients (%) | 32(17.0) | 156(83.0) | |
| Sex, no. (%) | |||
| Male: female ratio | 01:01.9 | 01:02.1 | 0.837 |
| Classification of diagnosis | |||
| PM | 5(15.6) | 37(23.7) | 0.363 |
| DM | 20(62.5) | 80(51.3) | 0.331 |
| ADM | 4(12.5) | 9(5.8) | 0.241 |
| OM | 2(6.25) | 24(15.4) | 0.261 |
| JM | 1(3.13) | 6(3.9) | 1 |
| Mean age ± S.D at onset (year) | 52.9 ± 15.8 | 41.9 ± 15.2 | 0 |
| Disease duration from onset to diagnosis, median (IQR) year | 3.8(2, 12.8) | 6.5(3, 12) | 0.215 |
| Skin ulcers, (%) | 6(18.8) | 15(9.6) | 0.212 |
| Complicated with ILD at disease course, (%) | 17(53.1) | 75(48.1) | 0.558 |
| Complicated with PAH at disease course, (%) | 3(9.4) | 17(10.9) | 1 |
| Complicated with malignancy, (%)e | 7(21.9) | 4(2.6) | 0 |
| Complicated with dysphagia at disease course, (%) | 8(25.0) | 67(42.9) | 0.074 |
| Cardiac involvement at disease course, (%) | 17(53.1) | 47(30.1) | 0.023 |
| Raynaud phenomenon at disease course, (%) | 4(12.5) | 25(16.0) | 0.79 |
| Low TP level† at diagnosis, (%) | 10(31.3) | 24(2.6) | 0.044 |
| Low ALB levels† at diagnosis, (%) | 16(50.0) | 46(29.5) | 0.038 |
| Elevated IgG†† at diagnosis, (%) | 8(25) | 47(30.1) | 0.672 |
| Elevated IgA†† at diagnosis, (%) | 9(28.1) | 25(15.4) | 0.122 |
| Elevated IgM†† at diagnosis, (%) | 5(15.6) | 20(12.8) | 0.775 |
| Creatine kinase at initial visit in our center, median (IQR) | 260.5 (71.8, 1173.8) |
491.5 (83.3, 1613.5) |
0.489 |
| Autoantibodies positive at disease course, (%) | |||
| ANA positive | 16(50.0) | 85(54.5) | 0.699 |
| Anti-RNP positive | 4(12.5) | 13(8.3) | 0.497 |
| Anti-Jo-1 positive | 0(0.0) | 24(15.4) | 0.016 |
| Anti-SSA positive | 2(6.3) | 33(21.2) | 0.048 |
| MYOACT global disease activity, 10-cm VAS score at disease onset | 6.21 ± 2.61 | 6.64 ± 2.60 | 0.408 |
| MYOACT muscle disease activity, 10-cm VAS score at disease onset | 7.09 ± 1.34 | 6.91 ± 1.3 | 0.47 |
| MYOACT, subscale VAS score > 0 at disease onset | |||
| Constitutional | 25(78.1) | 129(82.7) | 0.614 |
| Cutaneous | 25(78.1) | 111(71.2) | 0.518 |
| Skeletal | 10(31.3) | 42(26.9) | 0.666 |
| Gastrointestinal | 9(28.1) | 57(36.5) | 0.421 |
| Pulmonary | 4(12.5) | 12(7.7) | 0.483 |
| Cardiac | 9(28.1) | 35(22.4) | 0.497 |
†refers to values that are below the lower limit of normal laboratory assay standards.
††refers to values that are higher than the upper limit of normal laboratory assay.
ANA, antinuclear antibody; RNP, ribonucleoprotein; SSA: Sjögren's syndrome antigen.